We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 318 → 1 (-317)

100% less funds holding in top 10

Funds holding in top 10: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $10.5B → $159K (-$10.5B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 316

Holders
1
Holders Change
-317
Holders Change %
-99.69%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-28
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
316
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$943M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$890M
3
BlackRock
BlackRock
New York
-$824M
4
RG
Redmile Group
California
-$405M
5
FCM
Farallon Capital Management
California
-$394M
Name Holding Trade Value Shares
Change 		Change in
Stake
GAM
201
Gotham Asset Management
New York
– -$2.29M -49,334 Closed
AG
202
Aperio Group
California
– -$2.03M -43,774 Closed
HM
203
Harvest Management
New York
– -$1.97M -42,500 Closed
AC
204
Athanor Capital
New York
– -$1.89M -40,700 Closed
IA
205
IFG Advisory
Georgia
– -$1.88M -40,647 Closed
TD Asset Management
206
TD Asset Management
Ontario, Canada
– -$1.86M -40,064 Closed
OTPPB
207
Ontario Teachers' Pension Plan Board
Ontario, Canada
– -$1.85M -40,000 Closed
AB
208
Amalgamated Bank
New York
– -$1.85M -39,966 Closed
NSAM
209
North Star Asset Management
Wisconsin
– -$1.74M -37,600 Closed
AGM
210
Alpine Global Management
New York
– -$1.74M -37,500 Closed
XK
211
Xact Kapitalforvaltning
Sweden
– -$1.68M -36,278 Closed
QCMA
212
Quad Capital Management Advisors
New York
– -$1.68M -36,250 Closed
Envestnet Asset Management
213
Envestnet Asset Management
Illinois
– -$1.61M -34,825 Closed
BPB
214
Badgley, Phelps & Bell
Washington
– -$1.6M -34,500 Closed
SIM
215
Sonora Investment Management
Arizona
– -$1.58M -34,065 Closed
USAA
216
United Services Automobile Association
Texas
– -$1.56M -33,612 Closed
SBH
217
Segall Bryant & Hamill
Illinois
– -$1.54M -33,156 Closed
Public Employees Retirement Association of Colorado
218
Public Employees Retirement Association of Colorado
Colorado
– -$1.53M -32,963 Closed
Commonwealth Equity Services
219
Commonwealth Equity Services
Massachusetts
– -$1.43M -30,918 Closed
PPCM
220
Pillar Pacific Capital Management
California
– -$1.41M -30,440 Closed
WCM Investment Management
221
WCM Investment Management
California
– -$1.41M -30,406 Closed
Stifel Financial
222
Stifel Financial
Missouri
– -$1.4M -30,214 Closed
SSA
223
Schonfeld Strategic Advisors
New York
– -$1.34M -28,900 Closed
KCM
224
Kennedy Capital Management
Missouri
– -$1.33M -28,684 Closed
FFH
225
Fairfax Financial Holdings
Ontario, Canada
– -$1.27M -27,500 Closed
7 8
9
10 11

ARRY Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.

Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
  • The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.

Based on aggregated 13F filings for Q3 2019.